.

07 marzo 2007

Cáncer de Mama , La participación de la industria influye en los resultados de los ensayos clínicos .

Genoma del Cáncer , un paso más .

Investigadores de la Universidad de Navarra analizan un nuevo tipo de anticuerpos contra el cáncer .

Alzheimer , 25 Millones de casos en el Mundo , 800.000 en España .

MimoVax , Vacuna contra el Alzheimer , sera Financiada por la U.E.

Proteomic Analysis of the Resistance to Aplidin in Human Cancer Cells.

J Proteome Res. 2007 Mar 6

Proteomic Analysis of the Resistance to Aplidin in Human Cancer Cells.

Gonzalez-Santiago L ,Alfonso P, Suarez Y, Nunez A ,Garcia-Fernandez LF, Alvarez E, Munoz A, Casal JI .

Instituto de Investigaciones Biomedicas "Alberto Sols", Consejo Superior de Investigaciones Cientificas, Universidad Autonoma de Madrid, Arturo Duperier, 4, E-28029 Madrid, Spain, PharmaMar S.A., E-28770 Colmenar Viejo, Madrid, Spain, and Unidad de Tecnologia de Proteinas, Programa de Biotecnologia, Centro Nacional de Investigaciones Oncologicas (CNIO), Melchor FernAndez Almagro, 3, E-28229 Madrid, Spain.

Aplidin (plitidepsin) is an antitumoral agent that induces apoptosis via Rac1-JNK activation. A proteomic approach using 2D-DIGE technology found 52 cytosolic and 39 membrane proteins differentially expressed in wild-type and Aplidin-resistant HeLa cells, of which 39 and 27 were identified by MALDI-TOF mass spectrometry and database interrogation. A number of proteins involved in apoptosis pathways were found to be deregulated. Alterations in Rab geranylgeranyltransferase, protein disulfide isomerase (PDI), cystathionine gamma-lyase, ezrin, and cyclophilin A (CypA) were confirmed by immunoblotting. Moreover, the role of PDI and CypA in Aplidin resistance was functionally confirmed by using the inhibitor bacitracin and overexpression, respectively. These deregulated proteins are candidates to mediate, at least partially, Aplidin action and might provide a route to the cells to escape the induction of apoptosis by this drug. Keywords: Aplidin * differential proteomics * 2D-DIGE * chemoresistance * apoptosis pathways.

06 marzo 2007

Alzheimer , Jueves dia 8 de Marzo sera inagurado por los Reyes el Nuevo Centro del Pau de Vallecas .

Yondelis , Nueva Patente de Uso .

USES OF ET743 FOR TREATING CANCER

Publication number: SI1176964T
Publication date: 2007-02-28
Inventor: BOWMAN ANGELA DEPT OF CLINICAL (GB); CVITKOVIC ESTEBAN (FR); DEMETRI GEORGE DANIEL DEPT OF (US); GUZMAN CECILIA PHARMA MAR S A (ES); JIMENO JOSE PHARMA MAR S A (ES); LOPEZ LAZARO LUIS PHARMA MAR S (ES); MISSET JEAN LOUIS SERVICE D ON (FR); TWELVES C UNI OF GLASGOW CRC B (GB); VON HOFF DANIEL D ARIZONA CANC (US)
Applicant: PHARMA MAR SA (ES)
Classification: - international: C07D515/22; A61K31/4985; A61K31/4995; A61K35/56; A61P35/00; A61K31/495; C07D515/00; A61K31/4985; A61K31/4995; A61K35/56; A61P35/00;
- European: A61K31/4995; A61K35/56
Application number: SI20000030905T 20000515
Priority number(s): GB19990011183 19990513; GB19990011346 19990514; GB19990018534 19990805; GB19990027005 19991115; GB19990027106 19991116; GB20000007637 20000329; WO2000GB01857 20000515; EP20000927584 20000515